Sam Martin compensation by year
Celldex Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $490,790 |
| Bonus | $238,050 |
| Stock awards | $0 |
| Option awards | $1,087,449 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $10,823 |
| Total | $1,827,112 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Celldex Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001104659-26-050884, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 10,625 | — | $22.48 |
| Option | 81,000 | — | $19.53 |
| Option | 30,000 | — | $36.87 |
| Option | 50,625 | — | $36.43 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Celldex Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Celldex Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Voluntary resignation | $0 | $0 | $0 | $0 |
| Involuntary termination without cause | $529,000 | $0 | $62,406 | $591,406 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $1,058,000 | $667,755 | $62,406 | $2,145,236 |
| Resignation for good reason, no change in control | $529,000 | $0 | $62,406 | $591,406 |
Per the Potential Payments Upon Termination or Change in Control table in Celldex Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Celldex Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Anthony Marucci | President, Chief Executive Officer and Director | $5,366,709 |
| Tibor Keler | Executive Vice President and Chief Scientific Officer | $2,115,717 |
| Elizabeth Crowley | Senior Vice President, Chief Product Development Officer | $1,885,209 |
| Sam Martin · this page | Senior Vice President, Chief Financial Officer and Secretary | $1,827,112 |
| Margo Heath-Chiozzi | Senior Vice President, Regulatory Affairs | $1,820,359 |
The full Celldex Therapeutics compensation record
free company briefThis page is one person within Celldex Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Celldex Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Celldex Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat